Researchers at McMaster University conducted a phase 3 clinical trial, published in The New England Journal of Medicine, demonstrating that the oral GLP-1 receptor agonist orforglipron resulted in significant and sustained weight loss in obese adults without diabetes. The study, led by Dr. Sean Wharton, showed orforglipron produced greater weight reduction over 72 weeks compared to a placebo, with a safety profile similar to other GLP-1-based therapies. A separate study, involving investigators from McMaster University, Weill Cornell Medicine, and York University, among other institutions, also found that patients using an experimental oral GLP-1 drug experienced substantial weight loss and improvements in cardiovascular and metabolic risk factors. In unrelated news, a McMaster University startup, NodeAI, won the FACIT Falcons Pitch Competition for its artificial intelligence application designed to improve lung cancer diagnosis. Sean O’Brady, an assistant professor at the DeGroote School of Business at McMaster University, researches the effects of digitalization on job quality and well-being in the telecommunications and retail sectors.
Subscribe for full access to McMaster University's products in full detail
Subscribe for full access to McMaster University's revenue in full detail
Subscribe for full access to McMaster University's products in full detail 
